Papers/PMID:32592183
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Acta neurologica Scandinavica2020The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
cannabidiol — increases seizure frequency 50% responder rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The meta‐analysis results for the logistic regression on the 50% responder rate, the key secondary endpoint, also favored CBD vs. placebo regardless of CLB co‐therapy.”
Quoted verbatim from Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 10 or 20 mg/kg/day oral solution for 14 weeks
- Population
- Patients aged 2 to 55 years with Lennox-Gastaut syndrome or Dravet syndrome in four pooled phase 3 trials; CBD 10 and 20 mg/kg/day versus placebo, both CBD doses combined, analysed in strata with and without concomitant clobazam; antiseizure drugs continued in both arms
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.2020PMID:32592183Industry fundedPermalink